Applications

1744 – 177 Lutetium(nca)-DOTA-octreotate treatment for advanced neuroendocrine tumours and other high somatostatin receptor expressing tumours

Find out about the service or technology in this application and the medical condition it addresses. You can also view the application documents, the deadlines for providing consultation input and the outcome of the application when the MSAC process is complete.

  • Status Complete
  • Type New application
  • Pre-PASC consultation Closed
  • Pre-MSAC consultation Closed
  • Outcome Deferred

Application details

Reason for application

New MBS item.

Service or technology in this application

177 Lutetium(nca)-DOTA-octreotate is a radiopharmaceutical administered by infusion to patients with progressive or symptomatic Neuroendocrine Tumours (NET) if molecular imaging techniques demonstrate much higher levels of somatostatin receptors on the majority tumours sites compared to normal tissues.

The initial treatment cycle most commonly comprises 4-5 infusions, given 6-8 weeks apart, and responding patients may be re-treated multiple times if symptoms recur or further tumour progression occurs.

Type: Therapeutic technology

Medical condition this application addresses

Neuroendocrine tumours arise in a range of tissues from cells that function to regulate bodily function by secreting bioactive compounds, particularly peptide hormones.

These tumours can be slowly or aggressively growing with excessive hormone secretion often adversely affecting the patient’s quality of life in lower-grade tumours, while high-grade tumours cause compromise of organ function and tissue integrity leading to premature death.

Consultation survey and deadlines

  • PASC consultation: Closed
  • MSAC consultation: Closed Friday 14 June 2024
     

Meetings to consider this application

  • PASC meeting: 
    • 13–14 April 2023
    • 10–11 August 2023
  • ESC meeting: 
    • 13–14 June 2024
  • MSAC meeting: 
    • 1–2 August 2024
    • 28–29 November 2024